Monoclonal antibodies for chronic migraine and medication overuse headache : A real-world study
Copyright © 2023 Krymchantowski, Jevoux, Krymchantowski and Silva-Néto..
Background: Medication-overuse headache is highly prevalent in tertiary care centers. It may be a cause or consequence of the overuse of symptomatic medications for migraine attacks.
Objective: We aimed to compare the efficacy of anti-CGRP monoclonal antibodies (mAbs) added to conventional pharmacological treatments in patients with chronic migraine (CM) and medication overuse headache (MOH).
Methods: A cross-sectional, prospective, randomized, open study with real-world comparison groups of patients was carried out. The sample consisted of 200 patients with CM and MOH, who received the same approach to withdraw overused medications, started preventative treatment, and either did or did not receive mAbs.
Results: A total of 172 patients (126 women and 46 men) were included in the study and divided into two groups: group one consisting of 58 patients (control) and group two of 114 patients who used mAbs added to conventional pharmacological agents. The mean age was 44.1 ± 13.6 years, ranging from 18 to 78 years. In the 3 months follow-up after starting the treatment, both groups presented headache frequency reduction, but those with monoclonal antibodies had a significantly higher reduction in the number of headache days and symptomatic medication intake when compared to the control (p < 0.0001).
Conclusions: The addition of an anti-CGRP monoclonal antibody to the treatment for medication overuse headaches in chronic migraineurs may result in decreasing headache frequency and symptomatic medication use when compared to conventional treatments with drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in neurology - 14(2023) vom: 01., Seite 1129439 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Krymchantowski, Abouch V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic migraine |
|---|
| Anmerkungen: |
Date Revised 21.03.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fneur.2023.1129439 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354428993 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354428993 | ||
| 003 | DE-627 | ||
| 005 | 20231226062213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fneur.2023.1129439 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354428993 | ||
| 035 | |a (NLM)36937507 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Krymchantowski, Abouch V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monoclonal antibodies for chronic migraine and medication overuse headache |b A real-world study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Krymchantowski, Jevoux, Krymchantowski and Silva-Néto. | ||
| 520 | |a Background: Medication-overuse headache is highly prevalent in tertiary care centers. It may be a cause or consequence of the overuse of symptomatic medications for migraine attacks | ||
| 520 | |a Objective: We aimed to compare the efficacy of anti-CGRP monoclonal antibodies (mAbs) added to conventional pharmacological treatments in patients with chronic migraine (CM) and medication overuse headache (MOH) | ||
| 520 | |a Methods: A cross-sectional, prospective, randomized, open study with real-world comparison groups of patients was carried out. The sample consisted of 200 patients with CM and MOH, who received the same approach to withdraw overused medications, started preventative treatment, and either did or did not receive mAbs | ||
| 520 | |a Results: A total of 172 patients (126 women and 46 men) were included in the study and divided into two groups: group one consisting of 58 patients (control) and group two of 114 patients who used mAbs added to conventional pharmacological agents. The mean age was 44.1 ± 13.6 years, ranging from 18 to 78 years. In the 3 months follow-up after starting the treatment, both groups presented headache frequency reduction, but those with monoclonal antibodies had a significantly higher reduction in the number of headache days and symptomatic medication intake when compared to the control (p < 0.0001) | ||
| 520 | |a Conclusions: The addition of an anti-CGRP monoclonal antibody to the treatment for medication overuse headaches in chronic migraineurs may result in decreasing headache frequency and symptomatic medication use when compared to conventional treatments with drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic migraine | |
| 650 | 4 | |a erenumab | |
| 650 | 4 | |a fremanezumab | |
| 650 | 4 | |a galcanezumab | |
| 650 | 4 | |a medication-overuse headache | |
| 650 | 4 | |a monoclonal antibody | |
| 700 | 1 | |a Jevoux, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Krymchantowski, Ana Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Silva-Néto, Raimundo Pereira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in neurology |d 2010 |g 14(2023) vom: 01., Seite 1129439 |w (DE-627)NLM204500133 |x 1664-2295 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:01 |g pages:1129439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fneur.2023.1129439 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 01 |h 1129439 | ||